Tryp Therapeutics Strengthens IP Portfolio with Provisional Patent Application for Binge Eating Disorder Treatment Post published:June 29, 2022 Post category:Press Release
Tryp Therapeutics Initiates Enrollment for Binge Eating Disorder Study in Partnership with University of Florida Post published:March 23, 2022 Post category:Press Release
TRYP THERAPEUTICS INC. ANNOUNCES BOARD CHANGES AND CLOSING OF FIRST TRANCHE OF PRIVATE PLACEMENT Post published:February 22, 2022 Post category:Press Release
Tryp Therapeutics Announces Advancement of Phase 2a Clinical Trial in Binge Eating Disorder Post published:December 23, 2021 Post category:Press Release
Tryp Therapeutics Provides Update on Clinical Hold for Phase 2a Study for Eating Disorders Post published:November 18, 2021 Post category:Press Release
Tryp Therapeutics Submits IND Application for Phase 2a Clinical Trial in Fibromyalgia Post published:November 2, 2021 Post category:Press Release
Tryp Therapeutics Reports Clinical Hold on Proposed Phase 2a Study in Eating Disorders Post published:October 20, 2021 Post category:Press Release
Tryp Therapeutics Announces Collaboration with Researchers at the University of Wisconsin-Madison Post published:October 7, 2021 Post category:Press Release
Tryp Therapeutics Submits IND Application for Phase 2a Clinical Trial in Eating Disorders Post published:September 22, 2021 Post category:Press Release
Tryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the University of Florida Post published:August 24, 2021 Post category:Press Release